赛乐西帕合成路线图解

Graphical synthetic routes selexipag

赛乐西帕（selexipag,1）化学名称为2-[4-[N-（5,6-二苯基哌嗪-2-基）-N-异丙基氨基]丁氧基]-N-（甲磺酰基）乙酰胺,是一种选择性口服前列环素受体（IP受体）激动剂。该药由瑞士Actelion（爱可隆）生物制药公司研发,2015年12月21日获得美国FDA批准上市,商品名为Uptravi。赛乐西帕及其活性代谢产物对IP受体的选择性优于其他前列腺素受体，主要用于治疗肺动脉高压（PAH）。

Selexipag was developed by the Actelion Biopharmaceutical Company in Switzerland and approved by the U. S. FDA under the trade name Uptravi. The different routes for the synthesis of selexipag and its intermediates were reviewed.